BioPlus Acquisition Shares Will Open For Quote At 10:10 a.m. EST, Expected To Open For Trade After 10:20 a.m. EST; IPO Priced $10/Unit
BioPlus Acquisition Shares Will Open For Quote At 10:10 a.m. EST, Expected To Open For Trade After 10:20 a.m. EST; IPO Priced $10/Unit
BioPlus Acquisition Corp. (the "Company") announced today that it priced its upsized initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Global Market ("Nasdaq") and will begin trading tomorrow, Friday, December 3, 2021, under the ticker symbol "BIOSU". Each unit consists one of the Company's Class A ordinary shares and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one of the Company's Class A ordinary shares at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols "BIOS" and "BIOSW," respectively.
BioPlus Acquisition Corp.(以下简称“该公司”)今天宣布，其首次公开募股(IPO)规模扩大至2000万股，定价为每股10.00美元。这两家公司将在纳斯达克全球市场(“纳斯达克”)上市，并将于2021年12月3日(星期五)开始交易，股票代码为“BIOSU”。每个单位由一股本公司A类普通股和一半的一份可赎回认股权证组成，每份完整认股权证的持有人有权以每股11.50美元的价格购买一股本公司A类普通股。只有完整的权证可以行使，并将进行交易。一旦组成这两个单位的证券开始单独交易，A类普通股和权证预计将分别以“基本输入输出系统”和“BIOSW”代码在纳斯达克上市。
The Company is a blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the life sciences industry. The Company is led by Chief Executive Officer and Chief Financial Officer, Ross Haghighat, and Chairman of the Board and Chief Business Officer, Jonathan Rigby. Cantor Fitzgerald & Co. is acting as the sole book running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units at the initial public offering price to cover over-allotments, if any.
本公司是一家空白支票公司，其成立的目的是与一家或多家企业进行合并、股本交换、资产收购、股票购买、重组或类似的业务合并。虽然该公司可能会在任何业务或行业追求最初的业务合并目标，但它打算将重点放在生命科学行业的公司上。该公司由首席执行官兼首席财务官罗斯·哈格哈特和董事会主席兼首席商务官乔纳森·里格比领导。坎托·菲茨杰拉德公司(Cantor Fitzgerald&Co.)是此次发行的唯一账簿管理人。该公司已授予承销商45天的选择权，可按首次公开发行(IPO)价格额外购买至多300万个单位，以弥补超额配售(如果有的话)。
The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 5th Floor New York, New York 10022; Email: prospectus@cantor.com.
此次发行仅通过招股说明书进行。招股说明书的副本如有，可从坎托·菲茨杰拉德公司获得。注意：资本市场公司，地址：纽约公园大道499号，5楼，邮编：10022；电子邮件：proprotus@cantor.com。
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission ("SEC") on December 2, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
美国证券交易委员会(“美国证券交易委员会”)于2021年12月2日宣布与这些证券有关的注册声明生效。本新闻稿不应构成出售要约或征求购买要约，也不应在任何州或司法管辖区出售这些证券，在这些州或司法管辖区，根据任何州或司法管辖区的证券法，此类要约、招揽或出售在注册或获得资格之前是非法的。